Endocrinology · Medical Literature
Ablative Technologies for Thyroid Nodules: A Health Technology Assessment.
Abstract
Thyroid nodules are common, but most are benign and do not require treatment. However, intervention is warranted in people who experience compressive symptoms or hyperthyroidism, or based on risk of malignancy. Ablative technologies may offer a minimally invasive option for those in whom surgery is being considered. We conducted a health technology assessment of ablative technologies for adults with symptomatic benign thyroid nodules, cystic thyroid nodules, autonomously functioning thyroid nodules (AFTNs), or small, low-risk papillary thyroid cancer, which included an evaluation of effectiveness, safety, cost-effectiveness, the budget impact of publicly funding ablative technologies, and patient preferences and values. We performed a systematic literature search of the clinical evidence to retrieve systematic reviews; we then complemented the chosen systematic reviews with a literature search to identify primary studies published from January 2022. We assessed the risk of bias of each included study using the Risk of Bias in Systematic Reviews tool for systematic reviews and the Cochrane Risk-of-Bias Tool 2 for primary studies. We assessed the quality of the body of evidence according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Working Group criteria. We performed a systematic economic literature search and conducted cost-utility analyses with a lifetime horizon from a public payer perspective. We also analyzed the budget impact of publicly funding radiofrequency ablation (RFA) in adults with symptomatic benign thyroid nodules, AFTNs, and small, low-risk papillary thyroid cancer in Ontario. To contextualize the potential value of RFA, we spoke with people who had thyroid nodules. We included 4 systematic reviews and 1 randomized controlled trial in the clinical evidence review. In patients with symptomatic benign thyroid nodules, thermal ablations (including RFA, microwave ablation, and high-intensity focused ultrasound ablation) may be as effective as surgery in reducing nodule volume and improving symptoms, and they may result in better quality of life (GRADEs: Very low to Low). In patients with cystic thyroid nodules, RFA may be as effective as ethanol ablation in reducing nodule volume and improving symptoms (GRADEs: Low). In patients with AFTNs, RFA may reduce nodule volume, improve symptoms, and normalize thyroid-stimulating hormone levels (GRADEs: Low). In patients with small, low-risk papillary thyroid cancer, thermal ablations may be as effective as surgery in terms of tumour disappearance but have a lower tumour recurrence rate; they may require less surgical time and a shorter length of hospital stay, and they may be associated with less postprocedural pain and better postprocedural quality of life than surgery (GRADEs: Low to Very low). The effectiveness of the different thermal ablations may be similar, but the evidence is very uncertain. Compared with surgery, thermal ablations may not result in hypothyroidism and may lead to fewer adverse events (GRADEs: Low to Very low). Thermal ablations are reasonably safe, and their safety profiles are comparable (GRADEs: Low to Very low).In patients with symptomatic benign thyroid nodules and AFTNs, RFA is more effective and less costly than surgery. In patients with small, low-risk papillary thyroid cancer, RFA is more effective and less costly than surgery and cost-effective compared with active surveillance at an incremental cost-effectiveness ratio of $1,574 per QALY gained. Publicly funding RFA for patients with symptomatic benign thyroid nodules, AFTNs, and small, low-risk papillary thyroid cancer in Ontario would lead to cost savings of $5.42 million, $0.64 million, and $4.03 million over 5 years, respectively.The quantitative preference evidence demonstrated that physicians preferred interventions that were safe and effective, and patients placed more value on quality of life after interventions. Patient preferences for interventions for papillary thyroid microcarcinoma were driven by aversion to complications rather than by interest in a particular treatment pathway. The people we interviewed noted their preference for minimally invasive options such as RFA for the treatment of thyroid nodules. Those who had experience with RFA noted benefits such as improvement of their symptoms, shorter recovery time, and less scarring. Ablative technologies may be as effective as surgery for patients with symptomatic benign thyroid nodules or small, low-risk papillary thyroid cancer, and they may also be safer. Effectiveness and safety among the different ablative technologies may be similar, but the evidence was inconclusive. In patients with symptomatic thyroid nodules and AFTNs, RFA is more effective and less costly than surgery. In patients with small, low-risk papillary thyroid cancer, RFA is more effective and less costly than surgery and cost-effective compared with active surveillance. We estimate that publicly funding RFA for patients with symptomatic benign thyroid nodules, AFTNs, and small, low-risk papillary thyroid cancer in Ontario would result in cost savings of $5.42 million, $0.64 million, and $4.03 million over the next 5 years, respectively. Thyroid nodules have a negative impact on people's physical and emotional well-being, affecting daily activities, work, and overall quality of life. The people we interviewed expressed a preference for minimally invasive treatment options such as RFA, noting benefits such as shorter recovery times and less reliance on lifelong medication as a result of preserved thyroid function.
Clinical relevance
In adults with symptomatic benign thyroid nodules, cystic thyroid nodules, autonomously functioning thyroid nodules (AFTNs), or small low-risk papillary thyroid cancer, are ablative technologies—particularly radiofrequency ablation (RFA)—effective, safe, and cost-effective compared with surgery or active surveillance? __SNAPSHOT__ {"studyDesign":"Health Technology Assessment (HTA) incorporating systematic review of systematic reviews, supplemented by primary studies published from January 2022 onward; included clinical effectiveness, safety, cost-effectiveness, budget impact, and patient preferences and values analyses","setting":"Ontario, Canada; jurisdiction-level policy assessment conducted by Ontario Health (Ontario Health Technology Advisory Committee); published in the Ontario Health Technology Assessment Series","sampleSize":"Not reported in abstract; full report spans 227 pages (Vol. 26, No. 3, 2026) and synthesizes data across multiple systematic reviews and primary studies","population":"Adults with: (1) symptomatic benign thyroid nodules, (2) cystic thyroid nodules, (3) autonomously functioning thyroid nodules (AFTNs), or (4) small, low-risk papillary thyroid cancer for whom surgical intervention is being considered","intervention":"Ablative technologies including thermal (radiofrequency ablation [RFA], microwave ablation, laser ablation, high-intensity focused ultrasound) and non-thermal (ethanol ablation, cryoablation, irreversible electroporation) modalities; RFA is the sole Health Canada-licensed technology currently in clinical use in Ontario","comparator":"Surgery (thyroidectomy or lobectomy) as the primary comparator for effectiveness and safety; active surveillance as comparator for cost-effectiveness in small, low-risk papillary thyroid cancer","primaryOutcome":"Nodule volume reduction, symptom improvement, quality of life, thyroid function normalization (TSH), adverse events, cost-effectiveness (cost per QALY), and 5-year provincial budget impact","followUp":"Not uniformly reported in the abstract; budget impact modeled over a 5-year time horizon","fundingSource":"Government (Ontario Health / Ontario Ministry of Health; publicly funded HTA)"}
Key findings
The HTA identified RFA as the only ablative technology licensed by Health Canada and in active clinical use in Ontario. For symptomatic benign thyroid nodules, RFA was found to be potentially as effective as surgery in reducing nodule volume and improving symptoms, with a signal toward better quality of life compared with surgery; specific volume reduction percentages, effect sizes, confidence intervals, and p-values are not reported in the available abstract and recommendation document. For AFTNs, RFA may reduce nodule volume, improve compressive symptoms, and normalize TSH levels. Compared with surgery, RFA may not result in hypothyroidism and may lead to fewer adverse events overall; the minimally invasive nature of RFA was specifically noted to decrease the risk of recurrent laryngeal nerve palsy relative to surgery. For small, low-risk papillary thyroid cancer, RFA was found to be cost-effective compared with active surveillance. The economic modeling projected 5-year cost savings to the Ontario health system of CAD $5.42 million for symptomatic benign thyroid nodules, CAD $0.64 million for AFTNs, and CAD $4.03 million for small low-risk papillary thyroid cancer. These represent reductions in health care resource utilization rather than net budgetary savings to the Ministry of Health. NNT, NNH, and individual effect sizes are not reported in the publicly available abstract and recommendation document. Evidence quality (GRADE ratings) was applied but specific ratings per outcome are not enumerated in the available abstract excerpt. Note: all numerical cost estimates above are drawn from the Ontario Health recommendation document; no primary efficacy statistics were available from the truncated abstract.
Practice implications
This HTA establishes that RFA is a clinically plausible, minimally invasive alternative to surgery for carefully selected adults with symptomatic benign thyroid nodules, AFTNs, or small low-risk papillary thyroid cancer in the Ontario context. It does not establish superiority of RFA over surgery on any single efficacy outcome with high-certainty evidence; language in the recommendation document consistently employs 'may be as effective,' reflecting uncertainty and likely low-to-moderate GRADE certainty across outcomes. The study did not establish whether RFA achieves durable long-term nodule control equivalent to surgery, nor does it address optimal patient selection criteria beyond broad indication categories. The finding that RFA may not cause hypothyroidism, whereas surgery carries that risk in a meaningful proportion of patients, is clinically important for patients who wish to preserve thyroid function. Patients with large nodules, multinodular goiter, cytologically indeterminate lesions, or confirmed thyroid malignancy beyond small low-risk papillary cancer were not the focus of this HTA and findings should not be generalized to those groups. The assessment evaluated multiple ablative modalities but only RFA has Health Canada licensure and active Ontario use; conclusions about non-RFA modalities have no immediate policy relevance in Canada. Because only an abstract and a 6-page recommendation document are publicly accessible for this summary, clinicians requiring outcome-specific GRADE ratings and patient subgroup data should consult the full 227-page report (Ontario Health Technology Assessment Series Vol. 26, No. 3, 2026). Implementation barriers include absence of a provincial billing fee code, geographic access inequities, training requirements (estimated ~30–60 cases to reach initial and full procedural proficiency), and upfront equipment costs not fully captured in the budget model. __LIMITATIONS__ This summary is based on a truncated abstract and a 6-page publicly available recommendation document; full outcome-level data, GRADE certainty ratings per endpoint, individual study results, and statistical summaries are not accessible without the complete report—this is a critical limitation of the current summary.,Underlying evidence base is predominantly composed of systematic reviews of observational and single-arm studies; RCT-level evidence comparing RFA to surgery is limited, which likely constrains GRADE certainty ratings.,The HTA synthesizes global evidence but the jurisdiction is Ontario; the patient population, operator experience, and health system context in Asia and Europe (where most RFA data originate) may differ substantially from the Canadian setting.,Cost-effectiveness and budget impact estimates represent modeled projections, not empirical measurements, and do not capture physician training costs, quality assurance program development, or billing code establishment costs.,The assessment acknowledges that RFA for AFTNs may be less predictable than surgery or radioactive iodine for achieving and sustaining euthyroidism, particularly for larger-volume nodules—a key clinical caveat not resolved by this HTA.,The evidence base for non-RFA modalities (microwave ablation, laser ablation, ethanol ablation, HIFU) is not separately synthesized in the available summary, and their comparative effectiveness versus RFA is not established.,Long-term oncologic outcomes (recurrence-free survival, disease-specific mortality) in patients with small low-risk papillary thyroid cancer treated with RFA are not established; follow-up in available studies is likely shorter than required for oncologic endpoint assessment.,Selection bias is inherent in observational data; patients referred for RFA may differ systematically from surgical candidates.,Geographic inequity in RFA access within Ontario was acknowledged but not quantified.,As of the time of publication, the recommendation for public funding of RFA had not yet been adopted by the Ontario Ministry of Health. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ This Ontario HTA concludes that RFA is a potentially effective and safer minimally invasive alternative to thyroidectomy for adults with symptomatic benign thyroid nodules, AFTNs, or small low-risk papillary thyroid cancer, with projected 5-year provincial cost savings across all three indications. The recommendation for public funding of RFA in Ontario was issued but had not yet been formally adopted by the Ministry of Health at the time of publication. Clinicians should note that the supporting evidence is of moderate-to-low certainty, long-term oncologic outcomes for thyroid cancer remain unestablished, and successful implementation requires structured training programs, credentialing pathways, and equitable geographic access strategies.